Efficacy of immune checkpoint inhibitors for in-transit melanoma
نویسندگان
چکیده
منابع مشابه
Immune Checkpoint Inhibitors in Melanoma and HIV Infection
Introduction Immunotherapy with immune checkpoint inhibitors increases the overall survival of patients with metastatic melanoma regardless of their oncogene addicted mutations. However, no data is available from clinical trials of effective therapies in subgroups of melanoma patients that carry chronic infective diseases such as HIV. Evidences suggest a key role of the immune checkpoint molecu...
متن کاملGut microbiome modulates efficacy of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, which led to the limitation of clinical application. Motivated by potent and durable efficacy of ICIs, oncologists endeavor to explore the mechanisms of resistance to ICIs and increase the dru...
متن کاملCardiotoxicity of immune checkpoint inhibitors
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity. Immune checkpoint inhibitors are a novel class of anticancer drugs, distinct from targeted or tumour type-specific therapies. Cancer immunotherapy with immune checkpoint blockers (ie, monocl...
متن کاملBiomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
BACKGROUND Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have shown impressive therapeutic results. However, only 20-40% of advanced melanoma patients have durable responses to ICI, and these positive effects must be balanced against severe off-target immune toxicity and high costs. This urges the development of predictive biomarkers for ICI response to select patient...
متن کاملTNF-R1, an immune checkpoint in melanoma?
Through binding to and activation of two receptors, TNF-R1 and TNF-R2, Tumor Necrosis Factor α (TNF) modulates various biological processes in the immune system. A growing body of evidence in the literature indicates that TNF may behave as a tumorigenic cytokine, facilitating cancer cell immune escape and tumor progression. We have recently provided evidence that host TNF signaling impairs CD8+...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal for ImmunoTherapy of Cancer
سال: 2020
ISSN: 2051-1426
DOI: 10.1136/jitc-2019-000440